You are on page 1of 2

GLOBAL MARKET FOR CONGESTIVE HEART FAILURE DEVICES TO APPROACH $5.9 BILLION IN 2016 Wellesley, Mass.

According to a new technical market research report, GLOBAL MARKETS FOR DEVICES FOR TREATING CONGESTIVE HEART FAILURE (HLC095A) from BCC Research (www.bccresearch.com), the global market for devices that treat congestive heart failure was valued at $3.1 billion in 2010. It reached nearly $3.4 billion in 2011 and is expected to grow to nearly $5.9 billion by 2016, a five-year compound annual growth rate (CAGR) of 11.7%. The congestive heart failure device market can be broken down into four regions: the Americas, Europe, Asia, and the rest of the world. The region made up of the Americas accounted for nearly 52.5% of the market in 2010 and was valued at $1.6 billion. This market is expected to reach nearly $1.8 billion in 2011. BCC Research anticipates that the market will approach $3.2 billion by 2016, a five-year CAGR of 12.4%. The European region was valued at nearly $936 million in 2010 and increased to $1 billion by the end of 2011. This market is forecast to grow at a CAGR of 7.5% over the next five years to surpass $1.4 billion by 2016. The Asian region, worth $351.5 million in 2011, should grow at a CAGR of 19.6% to reach $858.5 million in 2016. The rest of the world segment was valued at $243.3 million in 2011 and in 2016 is expected to be $382.2 million after increasing at a CAGR of 9.5%. The heart beats an average of 72 times per minute, more than 103,000 times a day, and more than 2.6 billion times during a lifetime of 70 years. The heart is responsible for supplying oxygenated blood to all cells of the body through about 60,000 miles of blood vessels and for returning oxygen-poor blood to the lungs to be reoxygenated. Considering its size, the heart is doing an enormous amount of work. Congestive heart failure (CHF), also referred to as heart failure, is the inability of the heart to maintain sufficient cardiac output to optimally meet the metabolic demands of the tissues and organs of the body. Growth in all regions globally is anticipated for products that treat congestive heart failure for many reasons, including an aging population, increased incidence in all regions of CHF, availability of products to treat CHF, greater understanding of CHF, and overall rising demographics. Areas such as the United States and Europe are mature markets for CHF products, but rapidly aging populations and a rising incidence of CHF contribute to sustained growth. Meanwhile, emerging markets such as Brazil, India, China, and others are set to experience growth due to demographics, rising incomes, healthcare reform, and an increase in the treatment of CHF. In addition to HLC095A, BCC also has published HLC107A, HLC108A, HLC109A, and HLC110A. These reports cover congestive heart failure devices with focuses, respectively, on the Americas, Europe, Asia, and emerging market regions.

SUMMARY FIGURE TOTAL GLOBAL MARKET FOR CONGESTIVE HEART FAILURE DEVICES, 2010-2016 ($ MILLIONS)

Source: BCC Research Global Markets for Devices for Treating Congestive Heart Failure (HLC095A) Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49 Walnut Park, Building 2, Wellesley, MA 02481, Telephone: 866285-7215; Email: editor@bccresearch.com as the source and publisher, along with report number, which can be found in the first paragraph of this release. Thank you.

You might also like